Assenagon Asset Management S.A. Has $5.98 Million Holdings in Illumina, Inc. $ILMN

Assenagon Asset Management S.A. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 108.8% in the 1st quarter, Holdings Channel reports. The fund owned 48,508 shares of the life sciences company’s stock after acquiring an additional 25,273 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Illumina were worth $5,979,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Elyxium Wealth LLC acquired a new position in Illumina during the 4th quarter worth approximately $25,000. Board of the Pension Protection Fund acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC raised its holdings in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. bought a new stake in shares of Illumina in the fourth quarter worth $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of Illumina in the fourth quarter worth $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock valued at $155,710,908 in the last 90 days. 2.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ILMN shares. Evercore restated an “outperform” rating on shares of Illumina in a report on Friday, May 1st. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $125.00 to $185.00 in a research report on Wednesday, June 10th. Canaccord Genuity Group reduced their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Citigroup raised their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Finally, Guggenheim lifted their target price on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average target price of $146.00.

Illumina Price Performance

Shares of ILMN opened at $176.55 on Monday. The company has a market cap of $26.71 billion, a price-to-earnings ratio of 32.10, a PEG ratio of 3.30 and a beta of 1.50. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $182.84. The company’s fifty day simple moving average is $149.62 and its 200 day simple moving average is $137.73. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.